Literature DB >> 10849925

Risk factors for the development of adverse drug events in hospitalized patients.

P M van den Bemt1, A C Egberts, A W Lenderink, J M Verzijl, K A Simons, W S van der Pol, H G Leufkens.   

Abstract

Adverse drug events in hospitalized patients lead to increased morbidity, mortality and costs. Early detection of adverse drug events could aid in the prevention of these adverse outcomes. A cost-effective system for the early detection of adverse drug events should focus on high risk patients. A study was set up with the primary aim to identify characteristics that are associated with the development of adverse drug events (ADEs) in hospitalized patients. ADE reports were gathered from physicians and nurses (spontaneous reports) and from patients after intensive ward interviews by hospital pharmacists. All patients admitted to the internal medicine wards of two Dutch hospitals, during a two month period, were included. The following characteristics were analyzed for their potential relationship to the occurrence of ADEs: age (categorized), gender, number of drugs prescribed during hospital stay, types of drugs used and changes in drug use on admission. Age was found to be inversely associated with the development of ADEs (OR 0.36, CI 0.21-0.61 for age category > 80 years; OR 0.56; CI 0.31-1.02 for age category 75-80 years and OR 0.69; CI 0.42-1.11 for age category 60-74 years). Furthermore, statistically significant associations were found for the number of drugs prescribed per hospitalized patient (for the class of 4-6 drugs per patient OR 2.61, CI 1.32-5.18), for newly prescribed drugs (OR 6.65, CI 2.63-16.81) and for the cessation of drugs on hospital admission (OR 1.50, CI 1.02-2.20). The use of gastrointestinal drugs (OR 2.13, CI 1.32-3.45), central nervous system drugs (OR 1.66, CI 1.07-2.57) and antibiotics (OR 2.44, CI 1.65-3.60) were associated with the development of ADEs, when compared to all other drugs taken by the patients. In this study, the most important risk factors are the number of drugs used per patient and the starting of a new drug during hospitalization. As most hospitalized patients start new drug therapies while in hospital, this seems an inappropriate focus. However, careful monitoring of patients using more than 7 drugs at a time may be possible in a cost-effective system for the early detection of ADEs.

Entities:  

Mesh:

Year:  2000        PMID: 10849925     DOI: 10.1023/a:1008721321016

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  33 in total

1.  Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study.

Authors:  Asia N Rashed; Ian C K Wong; Noel Cranswick; Stephen Tomlin; Wolfgang Rascher; Antje Neubert
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Therapy related hospital admission in patients on polypharmacy in Singapore: a pilot study.

Authors:  Yvonne Koh; Bte Moideen Kutti Fatimah; Shu Chuen Li
Journal:  Pharm World Sci       Date:  2003-08

3.  Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands.

Authors:  Aileen B Dequito; Peter G M Mol; Jasperien E van Doormaal; Rianne J Zaal; Patricia M L A van den Bemt; Flora M Haaijer-Ruskamp; Jos G W Kosterink
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

4.  Polypharmacy among disabled Taiwanese elderly: a longitudinal observational study.

Authors:  Ding-Cheng Derrick Chan; Yi-Ting Hao; Shwu-Chong Wu
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care.

Authors:  Robyn Tamblyn; Allen Huang; Laurel Taylor; Yuko Kawasumi; Gillian Bartlett; Roland Grad; André Jacques; Martin Dawes; Michal Abrahamowicz; Robert Perreault; Nancy Winslade; Lise Poissant; Alain Pinsonneault
Journal:  J Am Med Inform Assoc       Date:  2008-04-24       Impact factor: 4.497

6.  Adverse reactions related to drugs for headache treatment: clinical impact.

Authors:  Anna Ferrari; Alessandra Ottani; Alfio Bertolini; Arrigo Francesco Giuseppe Cicero; Ciro Pio Rosario Coccia; Sheila Leone; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

Review 7.  Categorization and association analysis of risk factors for adverse drug events.

Authors:  Lina Zhou; Anamika Paul Rupa
Journal:  Eur J Clin Pharmacol       Date:  2017-12-08       Impact factor: 2.953

8.  Self-reported medication side effects in an older cohort living independently in the community--the Melbourne Longitudinal Study on Healthy Ageing (MELSHA): cross-sectional analysis of prevalence and risk factors.

Authors:  Jennifer A Thomson; Wei C Wang; Colette Browning; Hal L Kendig
Journal:  BMC Geriatr       Date:  2010-06-10       Impact factor: 3.921

9.  Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan.

Authors:  Mohammad Ismail; Zafar Iqbal; Muhammad Bilal Khattak; Muhammad Imran Khan; Hassan Arsalan; Arshad Javaid; Qamar Gul; Faramoz Khan
Journal:  Int J Clin Pharm       Date:  2013-03-13

10.  Evaluation of pharmacist clinical interventions in a Dutch hospital setting.

Authors:  Liesbeth Bosma; Frank G A Jansman; Anton M Franken; Johannes W Harting; Patricia M L A Van den Bemt
Journal:  Pharm World Sci       Date:  2007-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.